Medicare plans continue to rate high in overall satisfaction according to the results of a survey released by Caredata.com Inc., an Atlanta-based health care intelligence and Internet content provider.
Results of the 1999 Managed Medicare Member Survey show that, unlike commercial managed care plans where overall satisfaction has begun to decline, overall satisfaction for Medicare plans remains high.
The survey evaluated the satisfaction of Americans in Medicare HMOs, to which more than six million Americans now belong. Nearly 15,400 Medicare Plus Choice members participated in the survey, which was conducted from June through early October 1999 and evaluated 40 plans in 19 markets.
The results reveal that, despite some well-publicized pull-outs in some areas, satisfaction and re-enrollment intentions rose. When comparing 1999's results with 1998's, the survey found that 68.5% of respondents were highly satisfied in 1999, up from 66.9% in 1998, and 80.4% of those surveyed in 1999 were likely to re-enroll, whereas only 78.6% were willing to re-enroll according to 1998 findings.
Among all plans nationally, Harvard Pilgrim Health Care in Boston and California's Kaiser Permanente in California had the highest overall satisfaction rating. Harvard was also rated highest on specific issues such as "quality of medical care" and "customer service," while Kaiser was rated highest on "value for the money."
Said Mark Kaiser, chairman and CEO of Caredata.com, "With more than 30 million people eligible to enroll in Medicare Health Plans, access to the type of information released [in the survey] can be an important factor in determining which plan to join." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.